Shares tumble after the company announces a surprise acquisition.
News & Analysis: Progenics Pharmaceuticals
PGNX earnings call for the period ending June 30, 2019.
PGNX earnings call for the period ending March 31, 2019.
A phase 3 trial failed, but all isn't lost for the biotech.
Find out why these three biotech stocks could be huge winners.
The third quarter of 2018 will be awfully exciting for owners of these three stocks.
FDA approvals next month could be huge for these biotech stocks.
An FDA delay has investors worried.
An FDA decision is imminent.
The biotech progresses, but it should have been expected.